177lu-psma-617
novartis
[' vision', 'crpc', 'medsir']
dr. vaishampayan shares phase iii vision trial confirming efficacy of 177lu-psma-617 irrespective of prior regimen or soc in psma+ mcrpc, suggesting 177lu-psma-617 antitumor activity is driven by disease biology rather than prior &amp; concomitant treatment. #asco22 
Bring your idea to life?? 
Creating successful IITs & optimizing drug development ?? 
Medica Scientia Innovation Research
 ????&????
https://t.co/yp3O5Lylqc